FDA Approves New Glaucoma Treatment

The US Food and Drug Administration recently approved Rhopressa 0.02% (netarsudil ophthalmic solution) for the lowering of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
​____________________________________________________________________________________
RELATED CONTENT
1 Cup of Tea a Day Lowers Glaucoma Risk
Glaucoma: A Primary Care Review With a Focus on Medication Management
____________________________________________________________________________________
Rhopressa 0.02% is administer once a day using an eye dropper.

Common adverse effects included conjunctival hyperemia, corneal verticillata instillation site pain, and conjunctival hemorrhage.

—Melissa Weiss

Reference:

Aerie pharmaceuticals announces U.S. FDA approval of Rhopressa® (netarsudil ophthalmic solution) 0.02% for the lowering of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension [press release]. Irvine, CA: Aerie Pharmaceuticals; December 18, 2017. http://investors.aeriepharma.com/news-releases/news-release-details/aerie-pharmaceuticals-announces-us-fda-approval-rhopressar. Accessed December 19, 2017.